Literature DB >> 18089750

Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats.

Lioubov M Pletneva1, Otto Haller2, David D Porter1, Gregory A Prince1, Jorge C G Blanco1.   

Abstract

Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis in young children. In general, RSV is considered to be a poor inducer of type I (alpha/beta) interferons (IFNs). Measurement of active type I IFN production during infection in vivo is demanding, as multiple IFN subtypes with overlapping activities are produced. In contrast, Mx gene expression, which is tightly regulated by type I IFN expression, is easily determined. This study therefore measured Mx expression as a reliable surrogate marker of type I IFN activity during RSV infection in vivo in a cotton rat model. It was shown that expression of Mx genes was dramatically augmented in the lungs of infected animals in a dose- and virus strain-dependent manner. The expression of Mx genes in the lungs was paralleled by their induction in the nose and spleen, although in spleen no simultaneous virus gene expression was detected. Reinfection of RSV-immune animals leads to abortive virus replication in the lungs. Thus, type I IFN and Mx gene expression was triggered in reinfected animals, even though virus could not be isolated from their lungs. Furthermore, it was demonstrated that immunity to RSV wanes with time. Virus replication and Mx gene expression became more prominent with increasing intervals between primary infection and reinfection. These results highlight the role of type I IFN in modulation of the immune response to RSV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18089750      PMCID: PMC2741016          DOI: 10.1099/vir.0.83294-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  45 in total

Review 1.  Type I interferons and the innate immune response--more than just antiviral cytokines.

Authors:  Peter L Smith; Giovanna Lombardi; Graham R Foster
Journal:  Mol Immunol       Date:  2005-01-13       Impact factor: 4.407

2.  MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon.

Authors:  A Roers; H K Hochkeppel; M A Horisberger; A Hovanessian; O Haller
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

3.  Structure of the human type-I interferon gene cluster determined from a YAC clone contig.

Authors:  M O Díaz; H M Pomykala; S K Bohlander; E Maltepe; K Malik; B Brownstein; O I Olopade
Journal:  Genomics       Date:  1994-08       Impact factor: 5.736

4.  Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus.

Authors:  Antonieta Guerrero-Plata; Antonella Casola; Giovanni Suarez; Xiang Yu; LeAnne Spetch; Mark E Peeples; Roberto P Garofalo
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11-11       Impact factor: 6.914

5.  Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus.

Authors:  Jörg Schlender; Veit Hornung; Stefan Finke; Margit Günthner-Biller; Sabrina Marozin; Krzysztof Brzózka; Sharareh Moghim; Stefan Endres; Gunther Hartmann; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Expression of MxA protein in blood lymphocytes discriminates between viral and bacterial infections in febrile children.

Authors:  M Halminen; J Ilonen; I Julkunen; O Ruuskanen; O Simell; M J Mäkelä
Journal:  Pediatr Res       Date:  1997-05       Impact factor: 3.756

7.  Differential expression of human interferon genes.

Authors:  J Hiscott; K Cantell; C Weissmann
Journal:  Nucleic Acids Res       Date:  1984-05-11       Impact factor: 16.971

8.  Interferon production in adults with respiratory syncytial viral infection.

Authors:  C B Hall; R G Douglas; R L Simons
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

9.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

Authors:  F W Henderson; A M Collier; W A Clyde; F W Denny
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

10.  Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected].

Authors:  Kirsten M Spann; Kim-C Tran; Bo Chi; Ronald L Rabin; Peter L Collins
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  23 in total

1.  A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Stefanie N Vogel
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

2.  The cotton rat model of respiratory viral infections.

Authors:  Marina S Boukhvalova; Gregory A Prince; Jorge C G Blanco
Journal:  Biologicals       Date:  2009-04-25       Impact factor: 1.856

3.  Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice.

Authors:  Debby Kruijsen; Helga K Einarsdottir; Marcel A Schijf; Frank E Coenjaerts; Ellen C van der Schoot; Gestur Vidarsson; Grada M van Bleek
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

4.  Receptor characterization and susceptibility of cotton rats to avian and 2009 pandemic influenza virus strains.

Authors:  Jorge C G Blanco; Lioubov M Pletneva; Hongquan Wan; Yonas Araya; Matthew Angel; Raymonde O Oue; Troy C Sutton; Daniel R Perez
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

5.  Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.

Authors:  Marina S Boukhvalova; Talia B Sotomayor; Ryan C Point; Lioubov M Pletneva; Gregory A Prince; Jorge C G Blanco
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

6.  Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.

Authors:  Ibtissam Echchgadda; Te-Hung Chang; Ahmed Sabbah; Imad Bakri; Yuji Ikeno; Gene B Hubbard; Bandana Chatterjee; Santanu Bose
Journal:  BMC Cancer       Date:  2011-01-28       Impact factor: 4.430

7.  PROPHYLACTIC ANTIBODY TREATMENT AND INTRAMUSCULAR IMMUNIZATION REDUCE INFECTIOUS HUMAN RHINOVIRUS 16 LOAD IN THE LOWER RESPIRATORY TRACT OF CHALLENGED COTTON RATS.

Authors:  Jorge C G Blanco; Susan Core; Lioubov M Pletneva; Thomas H March; Marina S Boukhvalova; Adriana E Kajon
Journal:  Trials Vaccinol       Date:  2014

8.  Activation of innate immune antiviral responses by Nod2.

Authors:  Ahmed Sabbah; Te Hung Chang; Rosalinda Harnack; Victoria Frohlich; Kaoru Tominaga; Peter H Dube; Yan Xiang; Santanu Bose
Journal:  Nat Immunol       Date:  2009-08-23       Impact factor: 25.606

9.  Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota.

Authors:  Amanda J McFarlane; Henry J McSorley; Donald J Davidson; Paul M Fitch; Claire Errington; Karen J Mackenzie; Eva S Gollwitzer; Chris J C Johnston; Andrew S MacDonald; Michael R Edwards; Nicola L Harris; Benjamin J Marsland; Rick M Maizels; Jürgen Schwarze
Journal:  J Allergy Clin Immunol       Date:  2017-02-11       Impact factor: 10.793

10.  Human Adenovirus Type 4 Comprises Two Major Phylogroups with Distinct Replicative Fitness and Virulence Phenotypes.

Authors:  Camden R Bair; Wei Zhang; Gabriel Gonzalez; Arash Kamali; Daniel Stylos; Jorge C G Blanco; Adriana E Kajon
Journal:  J Virol       Date:  2021-07-07       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.